AstraZeneca, a leading pharmaceutical company based in the UK, has filed a lawsuit against the United States over legislation that would allow the government to negotiate prescription drug prices. The company claims that these new laws, known as the Inflation Reduction Act (IRA), are already forcing them to scale back investments in rare diseases and cancers. AstraZeneca, which generates 40% of its revenue from the US market, is the largest non-US drugmaker to take legal action against these measures.
Dave Fredrickson, executive vice president of oncology at AstraZeneca, emphasized that the IRA would have unintended consequences for patients with rare diseases and cancer in the US. He stated that the company is already reducing investments in small-molecule drugs, such as pills, due to the prospective legislation. Fredrickson stressed that this legal claim is not about preserving the industry's profits, but about standing up for Americans with rare diseases and cancers, as it fears that the implementation of the IRA would jeopardize the progress made in treating these conditions.
The IRA was introduced as a response to public pressure regarding high drug prices and aims to allow the US government to negotiate drug prices on behalf of Medicare patients, who are typically older or disabled Americans. This change is expected to save Medicare nearly $100 billion by 2031. However, pharmaceutical companies have warned that it will impact their profits and hinder their ability to invest in research for new therapies.
Studies have shown that consumers in the US pay more for prescription drugs compared to other countries, including Europe, where price negotiations between pharmaceutical companies and health systems are already in place. The US market is the most lucrative for many drug companies, making the potential impact of the IRA even more significant.
In addition to AstraZeneca, other major pharmaceutical companies, such as Johnson & Johnson, Merck & Co., and Boehringer Ingelheim GmbH, have also initiated legal challenges against the new US system. Merck argues that the measure is "tantamount to extortion," while Boehringer contends that the IRA violates the US Constitution by granting excessive power to federal regulators to dictate drug prices.
AstraZeneca specifically claims that the IRA will hinder research into rare diseases, citing the example of cancer medicines in the US that often launch for a small group of patients with unmet needs, known as orphan indications. The company argues that under the new regulations, they would have less time to exclusively sell these drugs. AstraZeneca warns that it may not have pursued approval for its drug, Lynparza, to treat late-stage ovarian cancer in the US if the IRA had been in effect at that time.
The US Department of Health and Human Services, responsible for overseeing the Medicare program, is expected to release a list of the first ten drugs for negotiation next week, with the new prices taking effect in 2026. It remains unclear which drugs will be included on this list. AstraZeneca's legal challenge underscores the concerns within the pharmaceutical industry regarding the impact of the IRA on research and the availability of treatments for rare diseases and cancers.